These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24866735)

  • 1. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure.
    Mittal S; Page SL; Friend PJ; Sharples EJ; Fuggle SV
    Am J Transplant; 2014 Jul; 14(7):1664-71. PubMed ID: 24866735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.
    Brooks AM; Carter V; Liew A; Marshall H; Aldibbiat A; Sheerin NS; Manas DM; White SA; Shaw JA
    Am J Transplant; 2015 Dec; 15(12):3239-46. PubMed ID: 26227015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Pancreas Transplant Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Alagusundaramoorthy S; Aziz F; Garg N; Redfield RR; Sollinger H; Kaufman D; Djamali A; Odorico J; Mandelbrot D
    Transplantation; 2019 Feb; 103(2):435-440. PubMed ID: 29994978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis of early pancreas graft failure via antibody-mediated rejection: single-center experience with 256 pancreas transplantations.
    de Kort H; Mallat MJ; van Kooten C; de Heer E; Brand-Schaaf SH; van der Wal AM; Roufosse C; Roelen DL; Bruijn JA; Claas FH; de Fijter JW; Bajema IM
    Am J Transplant; 2014 Apr; 14(4):936-42. PubMed ID: 24712331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome.
    Cantarovich D; De Amicis S; Akl A; Devys A; Vistoli F; Karam G; Soulillou JP
    Am J Transplant; 2011 Dec; 11(12):2737-46. PubMed ID: 21906255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.
    Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G;
    Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of de novo donor-specific anti-HLA antibodies on grafts outcomes in simultaneous pancreas-kidney transplantation.
    Malheiro J; Martins LS; Tafulo S; Dias L; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2016 Feb; 29(2):173-83. PubMed ID: 26404891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation.
    Morath C; Döhler B; Kälble F; Pego da Silva L; Echterdiek F; Schwenger V; Živčić-Ćosić S; Katalinić N; Kuypers D; Benöhr P; Haubitz M; Ziemann M; Nitschke M; Emmerich F; Pisarski P; Karakizlis H; Weimer R; Ruhenstroth A; Scherer S; Tran TH; Mehrabi A; Zeier M; Süsal C
    Front Immunol; 2020; 11():1886. PubMed ID: 32983110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The results of HLA-incompatible kidney transplantation according to pre-transplant crossmatch tests: Donor-specific antibody as a prominent predictor of acute rejection.
    Kwon H; Kim YH; Kim JY; Choi JY; Shin S; Jung JH; Park SK; Han DJ
    Clin Transplant; 2019 May; 33(5):e13533. PubMed ID: 30864255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
    Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
    Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Hla donor-specific antibody monitoring in pancreas transplantation: Role of protocol biopsies.
    Uva PD; Quevedo A; Roses J; Toniolo MF; Pilotti R; Chuluyan E; Casadei DH
    Clin Transplant; 2020 Aug; 34(8):e13998. PubMed ID: 32492226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
    Mujtaba MA; Fridell JA; Higgins N; Sharfuddin AA; Yaqub MS; Kandula P; Chen J; Mishler DP; Lobashevsky A; Book B; Powelson J; Taber TE
    Clin Transplant; 2012; 26(5):E492-9. PubMed ID: 22938159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation.
    den Dulk AC; Shi X; Verhoeven CJ; Dubbeld J; Claas FHJ; Wolterbeek R; Brand-Schaaf SH; Verspaget HW; Sarasqueta AF; van der Laan LJW; Metselaar HJ; van Hoek B; Kwekkeboom J; Roelen DL
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.